Semaglutide
The GLP-1 that redefined weight management.
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with a 165-hour half-life allowing convenient weekly dosing. It lowers blood glucose by enhancing glucose-dependent insulin secretion and suppressing glucagon, and it produces sustained weight loss by slowing gastric emptying and acting on hypothalamic appetite centers to reduce hunger and food-reward signaling. FDA-approved for type 2 diabetes and chronic weight management, it has demonstrated 15%+ mean body-weight reduction in the STEP trials, along with meaningful improvements in cardiovascular risk markers.
Clinical indications
- Appetite suppression
- Sustained weight loss
- Blood sugar control
- Reduced cravings
Titrate from 0.25 mg → 2.4 mg weekly subcutaneous
Suggested reference only. Final dosing is set by the prescribing clinician in our independent third-party network.